Literature DB >> 26083078

Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres.

Kieran Keohane1, Mónica Rosa2, Ivan S Coulter2, Brendan T Griffin1.   

Abstract

OBJECTIVES: Investigate the potential of coated minispheres (SmPill®) to enhance localized Ciclosporin A (CsA) delivery to the colon.
METHODS: CsA self-emulsifying drug delivery systems (SEDDS) were encapsulated into SmPill® minispheres. Varying degrees of coating thickness (low, medium and high) were applied using ethylcellulose and pectin (E:P) polymers. In vitro CsA release was evaluated in simulated gastric and intestinal media. Bioavailability of CsA in vivo following oral administration to pigs of SmPill® minispheres was compared to Neoral® po and Sandimmun® iv in a pig model. CsA concentrations in blood and intestinal tissue were determined by HPLC-UV.
RESULTS: In vitro CsA release from coated minispheres decreased with increasing coating thickness. A linear relationship was observed between in vitro CsA release and in vivo bioavailability (r(2) = 0.98). CsA concentrations in the proximal, transverse and distal colon were significantly higher following administration of SmPill®, compared to Neoral® po and Sandimmun® iv (p < 0.05). Analysis of transverse colon tissue subsections also revealed significantly higher CsA concentrations in the mucosa and submucosa using SmPill® minispheres (p < 0.05).
CONCLUSIONS: Modulating E:P coating thickness controls release of CsA from SmPill® minispheres. Coated minispheres limited CsA release in the small intestine and enhanced delivery and uptake in the colon. These findings demonstrate clinical advantages of an oral coated minisphere-enabled CsA formulation in the treatment of inflammatory conditions of the large intestine.

Entities:  

Keywords:  Bioavailability; coated minispheres; colonic targeting; mucosa; tissue

Mesh:

Substances:

Year:  2015        PMID: 26083078     DOI: 10.3109/03639045.2015.1044905

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  4 in total

Review 1.  Fundamental Aspects of Lipid-Based Excipients in Lipid-Based Product Development.

Authors:  Deepa Nakmode; Valamla Bhavana; Pradip Thakor; Jitender Madan; Pankaj Kumar Singh; Shashi Bala Singh; Jessica M Rosenholm; Kuldeep K Bansal; Neelesh Kumar Mehra
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

2.  Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Authors:  John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09

Review 3.  In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.

Authors:  Mauricio A García; Felipe Varum; Jozef Al-Gousous; Michael Hofmann; Susanne Page; Peter Langguth
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

Review 4.  Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs.

Authors:  Xingwang Zhang; Huijie Xing; Yue Zhao; Zhiguo Ma
Journal:  Pharmaceutics       Date:  2018-06-23       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.